Connect with us


Biotest Forecasts US Sales of Yimmugo of 936 Million Over the Next 7 Years

Biotest, a Grifols group company, expects $1 billion in US sales of its immunoglobulin drug Yimmugo over the next seven years, following FDA approval. Grifols shares rose 1.3% to nearly eight euros. Yimmugo will launch in Q1 2025, distributed by Kedrion, enhancing Grifols’ US growth strategy for treating immunodeficiencies.




Biotest, a company of the Grifols group, expects revenues of approximately one billion dollars (930.4 million euros) from sales in the United States of its intravenous immunoglobulin (Ig) Yimmugo over the next seven years, the blood derivatives company announced in a statement on Monday. Grifols shares rose by almost 1.3% on the stock market at around 1 p.m., reaching almost eight euros .

This forecast is part of the recent approval by the US Food and Drug Administration (FDA) of this drug to treat primary immunodeficiencies. The Catalan company recalls that Yimmugo is the first Biotest drug produced at the Next Level plant in Dreieich (Germany) to be marketed in the United States .

In this context, this plant has recently been certified by the FDA and already has approval for production and marketing in Europe, where Yimmugo has been sold since the end of 2022.

Yimmugo will be launched in the United States during the first quarter of 2025 and will be distributed by Kedrion thanks to a seven-year agreement with Biotest, which is part of the Grifols Group’s broad distribution strategy to ensure extensive reach and availability of its Ig therapies. He also recalled that the Grifols Group and Kedrion have a long-standing collaborative relationship .

Grifols considered Yimmugo a “key lever” for growth in the US market

With Yimmugo, the group’s US portfolio will have an “additional option” to address the growing demand for Ig to treat immunodeficiencies, which occur when a part of the body’s immune system is absent or does not function properly, and other diseases.

Grifols Biopharmaceutical Business Unit President Roland Wandeler said ensuring patients receive the best possible care is at the “core” of their mission. “Our distribution strategy will allow us to take full advantage of the availability of Grifols’ world-class intravenous and subcutaneous immunoglobulins across the United States, offering patients a broad range of effective treatments,” he added.

Following the launch of Yimmugo, considered a “key lever” in Grifols’ growth strategy in the United States, other proteins from the group will follow in this market, such as fibrinogen and trimodulin , both in an “advanced” phase of development.


(Featured image by Marek Studzinsky via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.